Scott Kinlay։ Cancer and Adverse Outcomes Over 5 Years After Coronary Stenting and Optimal DAPT Duration
Scott Kinlay, Chief of Cardiology at VA Boston Healthcare System and Associate Professor of Medicine at Harvard Medical School, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Just published: Ramael Ohiomoba and Edwin Mandieka’s paper examines the relationship of cancer to adverse outcomes over 5 years after coronary stenting, as well as the optimal duration DAPT.
Key findings were that cancer patients have higher rates of myocardial infarction and major bleeding after PCI compared to non-cancer patients. The analysis also supports a similar duration of DAPT after PCI in cancer patients as non-cancer patients.”
Title: Relationship of cancer and dual antiplatelet duration to long-term risk of ischaemic and bleeding outcomes after percutaneous coronary intervention
Authors: Ramael Ohiomoba, Edwin Mandieka, Melissa M Young, David R Gagnon, Scott Kinlay
Read the Full Article on European Heart Journal.
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 3, 2026, 16:05Abhishek Paserkar։ Revolutionizing Hypertriglyceridemia Treatment With Olezarsen
-
Feb 3, 2026, 15:52Maximo Agustin Schiavone: What Does ‘Risk-Factor-Free MI’ Really Mean in Practice?
-
Feb 3, 2026, 15:44Daniel Torrent: A New Path for ‘No-Optional’ Patients – TADV vs Standard of Care in CLTI
-
Feb 3, 2026, 15:11Latest News from the WHO Executive Board Session in Geneva – WFH
-
Feb 3, 2026, 14:54300 Million People, One Global Community – Rare Disease Day
-
Feb 3, 2026, 14:33Pedro Henrique Las Casas: VTE After BCMA Directed CAR T-Cell Therapy in Multiple Myeloma
-
Feb 3, 2026, 14:26Anuoluwapo Babalola։ What The U.S. Exit from WHO Means for Global Health Leadership
-
Feb 3, 2026, 14:16Michiel Voet: Why Every Military Should Have a Dedicated Blood Unit
-
Feb 3, 2026, 10:53Aurelio Maggio: The Final Chapter of Our Journey Through Thalassemia